Whitfield Advises SK Capital Partners on Acquisition of Apotex

Press Release   ·   28 September 2022

Overview

The source reports an SK Capital-affiliated fund’s agreement to acquire Apotex Pharmaceutical Holdings.

Target profile

Apotex is described as a Canadian pharmaceutical business supplying generic medicines across therapeutic areas and international markets.

Closing conditions

The announcement states that regulatory conditions remained to be satisfied and does not disclose a purchase price.

Advisory team

Matthew Arenson, Peter Stach and Jeremy Liss are identified as corporate leads, with specialists covering financing, tax, benefits, employment, real estate, environmental issues, technology and healthcare regulation. The record describes an announced agreement, rather than independently confirming completion or current ownership.